Now showing items 21-29 of 29

    • Noninvasive detection of HER2 amplification with plasma DNA digital PCR. 

      Gevensleben, H; Garcia-Murillas, I; Graeser, MK; Schiavon, G; Osin, P; Parton, M; Smith, IE; Ashworth, A; Turner, NC (2013-06)
      Purpose Digital PCR is a highly accurate method of determining DNA concentration. We adapted digital PCR to determine the presence of oncogenic amplification through noninvasive analysis of circulating free plasma DNA and ...
    • PIK3CA mutation enrichment and quantitation from blood and tissue. 

      Keraite, I; Alvarez-Garcia, V; Garcia-Murillas, I; Beaney, M; Turner, NC; Bartos, C; Oikonomidou, O; Kersaudy-Kerhoas, M; Leslie, NR (2020-10-13)
      PIK3CA is one of the two most frequently mutated genes in breast cancers, occurring in 30-40% of cases. Four frequent 'hotspot' PIK3CA mutations (E542K, E545K, H1047R and H1047L) account for 80-90% of all PIK3CA mutations ...
    • Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. 

      Fribbens, C; O'Leary, B; Kilburn, L; Hrebien, S; Garcia-Murillas, I; Beaney, M; Cristofanilli, M; Andre, F; Loi, S; Loibl, S; Jiang, J; Bartlett, CH; Koehler, M; Dowsett, M; Bliss, JM; Johnston, SRD; Turner, NC (2016-09)
      Purpose ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that ...
    • Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. 

      Lee, JY; Garcia-Murillas, I; Cutts, RJ; De Castro, DG; Grove, L; Hurley, T; Wang, F; Nutting, C; Newbold, K; Harrington, K; Turner, N; Bhide, S (2017-09)
      Background Following chemo-radiotherapy (CCRT) for human papilloma virus positive (HPV+) locally advanced head and neck cancer, patients frequently undergo unnecessary neck dissection (ND) and/or repeated biopsies for ...
    • Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer. 

      Hrebien, S; O'Leary, B; Beaney, M; Schiavon, G; Fribbens, C; Bhambra, A; Johnson, R; Garcia-Murillas, I; Turner, N (2016-01)
      Circulating tumor DNA (ctDNA) analysis has the potential to allow non-invasive analysis of tumor mutations in advanced cancer. In this study we assessed the reproducibility of digital PCR (dPCR) assays of circulating tumor ...
    • The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. 

      O'Leary, B; Cutts, RJ; Liu, Y; Hrebien, S; Huang, X; Fenwick, K; André, F; Loibl, S; Loi, S; Garcia-Murillas, I; Cristofanilli, M; Huang Bartlett, C; Turner, NC (2018-11)
      CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence ...
    • The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. 

      Barry, P; Vatsiou, A; Spiteri, I; Nichol, D; Cresswell, GD; Acar, A; Trahearn, N; Hrebien, S; Garcia-Murillas, I; Chkhaidze, K; Ermini, L; Huntingford, IS; Cottom, H; Zabaglo, L; Koelble, K; Khalique, S; Rusby, JE; Muscara, F; Dowsett, M; Maley, CC; Natrajan, R; Yuan, Y; Schiavon, G; Turner, N; Sottoriva, A (2018-10)
      Purpose: The most significant prognostic factor in early breast cancer is lymph node involvement. This stage between localized and systemic disease is key to understanding breast cancer progression; however, our knowledge ...
    • Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. 

      Fribbens, C; Garcia Murillas, I; Beaney, M; Hrebien, S; O'Leary, B; Kilburn, L; Howarth, K; Epstein, M; Green, E; Rosenfeld, N; Ring, A; Johnston, S; Turner, N (2018-01)
      Background:Selection of resistance mutations may play a major role in the development of endocrine resistance. ESR1 mutations are rare in primary breast cancer but have high prevalence in patients treated with aromatase ...
    • Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. 

      Pascual, J; Lim, JSJ; Macpherson, IR; Armstrong, AC; Ring, A; Okines, AFC; Cutts, RJ; Herrera-Abreu, MT; Garcia-Murillas, I; Pearson, A; Hrebien, S; Gevensleben, H; Proszek, PZ; Hubank, M; Hills, M; King, J; Parmar, M; Prout, T; Finneran, L; Malia, J; Swales, KE; Ruddle, R; Raynaud, FI; Turner, A; Hall, E; Yap, TA; Lopez, JS; Turner, NC (2020-09-21)
      Cyclin-dependent kinase 4/6 (CDK4/6) and PI3K inhibitors synergize in PIK3CA -mutant ER-positive HER2-negative breast cancer models. We conducted a phase Ib trial investigating the safety and efficacy of doublet CDK4/6 ...